The cystinosis therapeutic landscape continues to evolve gradually, although it remains largely dominated by long-established cysteamine-based treatments that have been the cornerstone of disease management for decades. These therapies, while effective in reducing cystine accumulation and improving survival outcomes, fall short of delivering curative or fully disease-modifying benefits. As a res..